Approval Package for:

APPLICATION NUMBER:

20-406/S007

Trade Name: Prevacid Delayed Release Capsules

Generic Name: (lansoprazole)

Sponsor: TAP Holdings Inc.

Approval Date: July 25, 1996
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Item</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 20-406/S007

APPROVAL LETTER
TAP Holdings Incorporated  
Attention: Judy Decker Wargel  
2355 Waukegan Road  
Deerfield, Illinois 60015

Dear Ms. Wargel:


We also acknowledge receipt of your amendment dated July 19, 1996.

The supplemental application provides for the removal of the from the approved 30 and 100 count bottles for both the 15 and 30 mg capsules.

We have completed the review of this supplemental application and it is are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Ms. Maria Walsh  
Consumer Safety Officer  
(301) 443-0487

Sincerely yours,

Eric P. Duffy, Ph.D.  
Acting Chemistry Team Leader  
Division of Gastrointestinal and Coagulation Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research
NDA 20-406/S-007
Page 2

CC:
NDA 20-406
HPD-180/Div.File
DISTRICT OFFICE
HFD-181/MWalsh
HFD-820/YChiu
HFD-180/GChen  GC 7/31/96
GC/dob F/T 7-23-96
R/D init: EDuffy/7-23-96
GC/dob F/T 7-23-96\WP: c:\wpfiles\chem\S\20406007.agc

APPROVAL
APPLICATION NUMBER:
NDA 20-406/S007

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
TAP Holdings Inc.
Attention: Judy Decker Wargel
2355 Waukegan Road
Deerfield, IL 60015

Dear Ms. Wargel:

We acknowledge receipt of your supplemental application for the following:

Name of Drug Product: Prevacid (lansoprazole) Delayed-Release Capsules.

NDA Number: NDA 20-406
Supplement Number: S-007
Therapeutic Classification: Standard
Date of Supplement: January 26, 1996
Date of Receipt: January 29, 1996

This supplement, submitted as "Special Supplement - Changes Being Effected" under 21 CFR 314.70(c), provides for the removal of the (b)(4) from the 30 and 100 count bottles.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on March 30, 1996 in accordance with 21 CFR 314.101(a).

All communications concerning this supplemental application should be addressed as follows:

Center for Drug Evaluation and Research
Division of Gastrointestinal and Coagulation Drug Products, HFD-180
Attention: DOCUMENT CONTROL ROOM
5600 Fishers Lane
Rockville, Maryland 20857
Should you have any questions, please contact me at (301) 443-0487.

Sincerely yours,

Maria Walsh
Consumer Safety Officer
Division of Gastrointestinal and Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

CC:
Original NDA 20-406/S-007
HFD-180/Div. Files
HFD-181/M.Walsh
DISTRICT OFFICE
Final: M.Walsh 2/2/96

SUPPLEMENT ACKNOWLEDGEMENT
January 26, 1996

Division of Gastrointestinal and Coagulation Drug Products, HFD-180
Document Control Room 6B-24
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Attn: Stephen B. Fredd, M.D.

RE: PREVACID® (lansoprazole) Delayed-Release Capsules
   NDA 20-406
   Supplement S-007
   Changes Being Effected

Dear Dr. Fredd:

The sponsor, TAP Holdings Inc., submits this Supplemental Application under
the provisions of Section 505 (i) of the Federal Food, Drug, and Cosmetic Act
and 21 CFR 314.70 (b) (3).

This is to notify the Agency that effective November 17, 1995, — is no longer being used in PREVACID 30 and 100 count bottles.

In your letter dated October 23, 1995, you agreed that it was acceptable to
make this change and notify the Agency in a “Changes Being Effected”
supplement.

Should you have any questions, please do not hesitate to contact me.

Sincerely,

Judy Decker Wargel
Associate Director, Regulatory Affairs
Phone: (847) 317-5781
Fax: (847) 317-5795

JDW/pjp